Advanced Cell Technology (ACT), a stem cell biotechnology company in Worcester, Massachusetts, showed the potential for cloning to contribute to conservation efforts. In 2000 ACT researchers in the United States cloned a gaur (Bos gaurus), an Asian ox with a then declining wild population. The researchers used cryopreserved gaur skin cells combined with an embryo of a domestic cow (Bos taurus). A domestic cow also served as the surrogate for the developing gaur clone. The successful procedure opened the opportunity to clone individuals from species for which there are few or zero live specimens. The official release of this experiment's data was published in the paper 'Cloning of an Endangered Species (Bos gaurus) Using Interspecies Nuclear Transfer,' in October 2000. In the article, the researchers presented data collected from several cloned fetuses that were aborted before the full term of 283 days. At the time of publication, the gaur bull fetus, named Noah at birth, had developed for greater than 180 days. Noah was born on 8 January 2001, but died two days later due to dysentery. The development, birth, and death of Noah became a platform for conservationists and ethicists to critique the role of cloning in society and as a method to conserve species.
During the twentieth and twenty-first centuries, Robert Paul Lanza studied embryonic stem cells, tissues, and endangered species as chief scientific officer of Advanced Cell Technology, Incorporated in Worcester, Massachusetts. Lanza's team cloned the endangered species of gaur Bos gaurus. Although the gaur did not survive long, Lanza successfully cloned another cow-like creature, called the banteng (Bos javanicus). Lanza also worked on cloning human embryos to harvest stem cells, which could be used to treat dieases. While previous techniques required the embryo's destruction, Lanza developed a harvesting technique that does not destroy the embryo, forestalling many ethical objections to human embryonic research.
Advanced Cell Technology, Inc. (ACT) is a biotechnology company that uses stem cell technology to develop novel therapies in the field of regenerative medicine. Formed in 1994, ACT grew from a small agricultural cloning research facility located in Worcester, Massachusetts, into a multi-locational corporation involved in using both human embryonic stem cells (hESC) and human adult stem cells as well as animal cells for therapeutic innovations. Through its work in developing alternative methods for hESC derivation and its public statements, ACT has also played an active role in stimulating and participating in public debate over stem cell research.